RCS - IXICO plc - Late phase clinical study in Huntington's disease

IXICOAnnouncement

05/03/2019 07:05

RNS Number : 7703R
IXICO plc
05 March 2019
 


5th March
IXICO plc
("IXICO" or the "Company")
 
IXICO continues to be first choice for imaging services in Huntington's disease
 
Chosen to support a late phase clinical research programme, adding £0.5m in revenues
 
IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, today announces that it has been confirmed as the provider of data analytics and neuroimaging services to support the ongoing treatment of participants in a late phase clinical research programme in Huntington's disease. IXICO's unique service offering and expertise will be employed in an extension study to allow people living with the disease to continue to contribute to the search for a treatment for this condition.  
 
The agreement, which accentuates IXICO's momentum in Huntington's disease, will generate additional revenues of £0.5m during the course of the study.
 
Giulio Cerroni, Chief Executive Officer of IXICO, commented:
"We are pleased to announce our involvement in this late phase clinical study, which supports the search for an effective treatment of Huntington's disease. The announcement emphasises our partner-of-choice status in neurodegenerative data analytics and our capabilities across all stages of clinical development."
 
 
For further information please contact:
 



IXICO plc
Giulio Cerroni, Chief Executive Officer


 
Tel: +44 20 3763 7498














FTI Consulting Limited (Investor Relations)
Simon Conway / Victoria Foster Mitchell / Tim Stamper


Tel: +44 20 3727 1000



 
 
About IXICO
 
IXICO is dedicated to delivering insights in neuroscience. Our mission is to transform the progression of our biopharmaceutical clients' neurological therapeutic pipelines through the application of novel medical imaging and mobile health digital technologies.
 
IXICO's data analytics services are used by the global biopharmaceutical industry to interpret data from brain scans and digital biosensors to enable better trial design, site qualification, patient selection and clinical outcomes. We provide technology-enabled services across all phases of clinical evaluation. Our integrated digital platform provides a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable clients to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new analytical techniques and companion digital health products targeted at improving patient outcomes.
 
More information is available on www.IXICO.com




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAUGUMPWUPBGPC